Posts for Ticker ‘THLD’

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Posted on: April 17, 2009 – 2:05 pm in Biotech, Calendar, Drug companies, , , , , , , , , , , , , , , , , , ,

Biotechs & Pharmas Bracing For ASCO Annual Meeting

This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology.  Cancer stocks in the last few weeks have been seeing a muted response ahead of the event that biotech investors have traditionally braced for.  At various points on the website you can find a full list of contributing and presenting companies.  This is only a sample of the companies presenting data and it is very possible that the dates and even the companies may have changed.  Also, you’ll probably start seeing news here at this ASCO News Site either late Thursday evening or Friday. Some of these dates and presentation schedules have been compiled over a multi-week period, so it is very likely that some of these will have changed.

SATURDAY, JUNE 2

Genentech (DNA) will show data with Roche on Avastin plus a chemotherapy dual-mix cocktail for first line treatment in non-small cell lung cancer patients.  Later on at ASCO, a failed Avastin study for the treatment of pancreatic cancer will be shown.  Some Phase III Avastin data in kidney cancer will also be presented next week. Genentech will also be showing data with partners OSI Pharmaceuticals (OSIP) and Imclone (IMCL) in later days.

Pfizer (PFE) will present data on Sutent’s safety and efficacy in Phase II liver cancer studies.

If you forgot about Dendreon (DNDN), this will be the company’s last known data presentation on Provenge after getting the FDA delay.  Investors will be looking closely at any ‘New Data’ presented because much of the ongoing study data is being treated as old data.

Arqule (ARQL) and Exelixis (EXEL) are presenting data as well on molecules that are deemed cancer targets

Others to watch are Onyx Pharmaceuticals (ONXX) and partner Bayer (BAY), because their liver cancer studies are under concern over toxicity.  Its Nexavar data will be presented later for liver cancer Phase III.

Amgen (AMGN) will have study posters up discussing safety of its anemia treatment Aranesp that many patients have to use.  It is no secret that the reimbursement rates, effectiveness and safety, and the dosage have been under fire and worse for some time now.  Most of the damage has been done and many feel that more cautionary and worrisome days are ahead.

Immunogen (IMGN) will be releasing some preliminary data on Herceptin-DM1 in its Genentech pact for the treatment of breast cancer.

Read More »

Posted on: May 30, 2007 – 6:30 pm in Biotech, , , , , , , , , , , , , , , , , , , ,